期刊文献+

Preliminary study of the mechanism of isolinderalactone inhibiting the malignant behavior of bladder cancer

原文传递
导出
摘要 Background:Isolinderalactone(ILL),extracted from the dried tubers of Linderae aggregate,has multiple functions,such as antioxidation,antitumor,and anti-infection effects.However,there have been fewstudies on ILL's antitumor role and no reports on its role in bladder cancer(BC).Materials and methods:Human BC cell lines T24 and EJ-1 were treated with different concentrations of ILL(0,10,20,50,100,200,400,600,800,and 1000μmol/L),and the cell proliferation inhibition rate was analyzed using the CCK-8 assay.The effect of ILL on T24 and EJ-1 cell cycle inhibition and apoptosis was examined using flow cytometry.Immunoblotting was used to detect the levels of apoptosis-related proteins,BAX,BAK1,and CYCS,in BC cells of the control and ILL-treated groups,and quantitative PCR experiments were performed to detect the apoptosis-related gene expression of CASP10,CYCS,BAX,BCL-2,CASP8,and BAK1.T24 and EJ-1 tumor-bearingmousemodels were established and divided into vehicle control,low-dose(10mg/kg)and high-dose(20mg/kg)groups,with 5 mice in each group.Hematoxylin and eosin staining and immunohistochemistry were used to detect changes in apoptosisrelated proteins in vivo.Results:The CCK-8 assay showed that in vitro,ILL significantly inhibited the proliferation of the T24 and EJ-1 BC cell lines.Flowcytometry and immunoblotting results showed that ILL increased mitochondrial permeability by upregulating proapoptotic proteins BAK1 and BAX,promoting CYCS release and significantly inducing cell cycle arrest at G0/G1 phase.In vivo,on day 25 of administration,tumor inhibition rates in T24 and EJ-1 tumor-bearing mice were up to 75.24% and 47.43%,respectively,in the ILL high-dose-treated and 71.58% and 43.89%,respectively,in the ILL low-dose-treated groups.Conclusions:Isolinderalactone controls BC progression by inducing apoptosis,suggesting that ILL may be an effective drug for the treatment of BC.
机构地区 Department of Urology
出处 《Current Urology》 2025年第1期49-58,共10页 当代泌尿学(英文)
基金 supported by the Fundamental Research Funds for the Central Universities(No.buctrc201910) Young Elite Scientists Sponsorship Program by Xinjiang Association for Science and Technology(2021) basic research program of Yunnan Science and Technology Department and Kunming Medical University(202101AY070001-144) the scientific research project of Education Department of Yunnan Province(No.2024Y231).

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部